Generate Biomedicines Inc. (GENB), which recently debuted on the Nasdaq, continues to advance its clinical pipeline across multiple therapeutic areas, modalities, and both wholly owned and partnered programs.
This clinical-stage generative biology company is pioneering the AI revolution in drug design and development. Its clinical-stage programs enabled by its AI Technology Platform include GB-0895, GB-4362, and GB-5267.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com